Celgene Stock Hits New High On Analyst Upgrades
Shares of Celgene (CELG) were trading at an all-time high early Tuesday after a slew of analyst upgrades followed its investor presentation Monday. At the JPMorgan Healthcare Conference in San Francisco, the biotech issued financial guidance all the way out to 2017, when it predicted annual revenue will have more than doubled to $12 billion. It also said its psoriasis drug candidate Apremilast met the desired endpoints in its phase-three trials,
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here